U.S. markets open in 4 hours 24 minutes

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.4800+0.0800 (+5.71%)
At close: 04:00PM EST
1.5200 +0.04 (+2.70%)
Pre-Market: 04:04AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.4000
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range1.4001 - 1.5000
52 Week Range1.0500 - 29.2500
Avg. Volume175,986
Market Cap10.832M
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)-0.3350
Earnings DateFeb 15, 2023 - Feb 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TTOO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • T2 Biosystems, Inc.
    Analyst Report: Becton, Dickinson and CompanyBecton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 24% of revenue. International revenue accounts for 43% of the company's business.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • GlobeNewswire

    T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize

    LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation’s (“Cohen Foundation”) LymeX Diagnostics Prize. The goal of the multiphase LymeX Innovation Accelerator (LymeX) prize competition is to nurture the devel

  • GlobeNewswire

    T2 Biosystems Reports Granting of Inducement Award

    LEXINGTON, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, and antibiotic resistance genes, announced today that it issued inducement awards to fourteen new employees. The awards were made on January 30, 2023, under the T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted on March 1, 2018 and amended and restated on December 17, 2021 and provides for the granting of equity awards to

  • GlobeNewswire

    T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results

    Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year 2022 and Recent Highlights (unaudited) Achieved full year 2022 total revenue of $22.3 million, including prod